ArticleOpen veterinary journal2025
Functional assessment of kidneys and liver functions in lambs treated with zinc oxide nanoparticles.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zinc oxide nanoparticles (ZnO NPs) have low toxicity and are utilized extensively in medicine. The properties of ZnO NPs include the promotion of growth, the modulation of the immune system, and the regulation of animal reproduction. Aim: An evaluation of the renal and hepatic function of lambs subjected to ZnO NP treatment. Methods: Fifteen apparently healthy local breed lambs, aged between 7 and 9 months, were utilized in the present study. The lambs were divided randomly into three equal groups. The control group (group I) received water and glycerol only, the treatment group (group II) received 3.5 mg/kg of ZnO NPs orally, and the third group (group III) received 7 mg/kg of ZnO NPs orally once daily for a period of 90 days. A comprehensive biochemical analysis encompasses a range of essential parameters, including aspartate aminotransferase (AST); alanine aminotransferase; alkaline phosphatase (ALP); serum creatinine; blood urea; and total serum bilirubin (TSB). Results: A significant increase in TSB was observed among the control group (I) in comparison with the initial baseline. Furthermore, a significant increase in TSB. was noted in group I when it was incorporated with groups II and III at the end of the study. A significant increase in serum AST and ALP was observed among groups I, II, and III at the study's conclusion in comparison with the initial baseline. However, no significant changes were detected between these groups. Conversely, serum ALP values exhibited a significant decrease at the study's conclusion in comparison with the baseline. There was a substantial increase in serum urea and creatinine levels at the end of the study in all groups when compared with the baseline. Conclusion: Due to the different results of toxicological studies on experimental animals. Current recommends carrying out more studies to clarify the toxic effects, in order to install the appropriate doses for animals to determine the desired benefit of nano-zinc to reach logical conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.